Roche extends Spark Therapeutics' offer worth 4.3 billion USD
Roche needs to get at least a majority of outstanding Spark stock for the offer to go through.
ZURICH: Roche Holding has extended until May 2 its $4.3 billion offer for U.S. gene therapy specialist Spark Therapeutics, the Swiss drugmaker said after getting only 29.4 per cent of Spark's shares in a tender originally due to end on Wednesday.
Roche needs to get at least a majority of outstanding Spark stock for the offer to go through.
Read Also: Diabetes Test Strips Fraud: Roche sues US executives for $84 million
"All terms and conditions of the offer shall remain unchanged during the extended period," Roche said in a statement on the $114.50 per share offer it announced in February.
Spark shares closed at $114.01 on Tuesday.
Read Also: Roche Tecentriq, chemotherapy combo wins USFDA approval for treatment of lung cancer
Roche offered more than twice the Philadelphia-based company's closing price on Feb. 22 for a portfolio that includes a blindness treatment that has U.S. and European approval and other projects for haemophilia and neurodegenerative disorders like Huntington's disease.
The offer comes as rivals, including Novartis, also move aggressively into gene therapy, where treatments for rare, inherited diseases command some of the highest prices in medicine. Spark's blindness therapy Luxturna is priced at $850,000 per patient.
Read Also: Roche gets European approval for Tecentriq in combo with Avastin, chemotherapy
Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd